Smarter. Stronger. Together: Educating Providers and Patients to Optimize the Use of Targeted Oral Therapies for HR+/HER2- Breast Cancer

Gain perspectives on strategies for optimizing use of CDK4/6 and PI3K inhibitors for HR+/HER2- breast cancer including discussion on effective patient education about these targeted oral therapies! Learn from the experts with downloadable slides commentaries podcast on-demand Webcast and an Interactive Decision Support Tool providing personalized management recommendations for adverse events associated with CDK4/6 and PI3K inhibitors.

Resources for your patients: https://www.smartpatients.com/resources/cco-breast-cancer

Share

Program Content

No activities added yet

Activities

Use of Targeted Oral Therapies for HR+/HER2- Breast Cancer
Smarter. Stronger. Together: Educating Providers and Patients to Optimize the Use of Targeted Oral Therapies for HR+/HER2- Breast Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 05, 2021

Expires: March 04, 2022

<i>EP</i>: Use of Targeted Oral Therapies for HR+/HER2- Breast Cancer
ExpressPoints: Educating Providers and Patients to Optimize the Use of Targeted Oral Therapies for HR+/HER2- Breast Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 09, 2021

Expires: March 08, 2022

Activities

CDK4/6i for HR+/HER2- MBC
Expert Insights on Optimal Use of CDK4/6 Inhibitors for HR-Positive/HER2-Negative Breast Cancer
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: August 19, 2021

Expires: August 18, 2022

<i>PodcastPearls</i>: CDK4/6i Slideset
PodcastPearls: Expert Insights on Optimal Use of CDK4/6 Inhibitors for HR-Positive/HER2-Negative Breast Cancer
Podcast Episodes
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: August 24, 2021

Expires: August 23, 2022

Activities

CDK4/6i and PI3Ki in HR+/HER2-
CDK4/6 and PI3K Inhibitors for HR+/HER2- Breast Cancer in the Clinic Today: Thoughts From the Experts
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: March 23, 2021

Expires: March 22, 2022

Abemaciclib in EBC
What to Know About the New Approval for Abemaciclib in Patients With Early Breast Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: November 29, 2021

Expires: November 28, 2022

Activities

Managing AEs: Oral Targeted Tx in HR+, HER2– BC
An Interactive Tool for Managing AEs With Oral Targeted Therapies for HR+, HER2– Breast Cancer
Tool
Congratulations: You achieved a completion on 04/09/2022

Released: September 14, 2021

Expires: September 13, 2022

Faculty

cover img faculity

Donna M. Fitzgerald, PA-C, MPAS

Physician Assistant
Termeer Center for Targeted Therapies
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

cover img faculity

Matthew P. Goetz, MD

Professor of Oncology and Pharmacology
Director, Mayo Breast Cancer SPORE
Co-PI, Womens Cancer Program
Department of Medical Oncology
Mayo Clinic
Rochester, Minnesota

cover img faculity

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

cover img faculity

Marissa Marti-Smith, APRN, AGNP-C, AOCNP

Nurse Practitioner
Breast Oncology
Texas Oncology Baylor Sammons Cancer Center
Dallas, Texas

cover img faculity

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Sarah Cannon Research Institute
Texas Oncology
Dallas, Texas

cover img faculity

Laura M. Spring, MD

Breast Medical Oncologist
Mass General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Supporters

Supported by an educational grant from

Lilly

Partners

Smart Patients

ProCE Banner